ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
48.60
+0.55 (+1.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close48.05
Open48.05
Bid48.20 x 1800
Ask60.85 x 1800
Day's Range47.10 - 49.05
52 Week Range11.40 - 62.75
Volume1,228,156
Avg. Volume774,685
Market Cap2.033B
Beta1.94
PE Ratio (TTM)N/A
EPS (TTM)-4.37
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est75.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Mallinckrodt Public and Zogenix

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-18 8:30pm GMT

    Q2 2018 Zogenix Inc Earnings Call

  • GlobeNewswire12 days ago

    Zogenix Prices Public Offering of Common Stock

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $52.00 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be $312,000,000.  Zogenix has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are being sold by Zogenix.

  • Associated Press13 days ago

    Zogenix: 2Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of 83 cents per share. Losses, adjusted to account for discontinued operations, were 82 cents per share. The results beat Wall Street expectations. ...

  • GlobeNewswire13 days ago

    Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are to be sold by Zogenix.

  • GlobeNewswire13 days ago

    Zogenix Provides Corporate Update and Reports Second Quarter Financial Results

    Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated ...

  • ACCESSWIRE13 days ago

    Zogenix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Zogenix, Inc. (NASDAQ: ZGNX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To listen ...

  • GlobeNewswire18 days ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    The awards were made on August 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 32,000 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $56.20, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • GlobeNewswire18 days ago

    Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6

    EMERYVILLE, Calif., Aug. 01, 2018-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system disorders, today announced that it will report its financial ...

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatchlast month

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • 3 Very Popular Marijuana Stocks on My "Do Not Buy" List
    Motley Foollast month

    3 Very Popular Marijuana Stocks on My "Do Not Buy" List

    Not all pot stocks will have investors seeing green.

  • Motley Foollast month

    Is Marijuana the Best Medicine for Epilepsy?

    A new marijuana-based drug will soon be available for some epilepsy patients, but another drug might work even better.

  • Motley Foollast month

    These Epilepsy Drugmakers Are About to Brawl

    A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.

  • 3 Big-Name Marijuana Stocks With Plunging Profit Projections
    Motley Foollast month

    3 Big-Name Marijuana Stocks With Plunging Profit Projections

    Investors may not see as much green with these pot stocks as once expected.

  • ACCESSWIRElast month

    The Market That Took BEAT Higher By 800% Could Do The Same For This Strong New Competitor

    Cardiac monitoring is a $32 billion market, and the companies that are successfully navigating this space with new technology are seeing huge returns: IRTC is up 300% in 3 years, and BEAT up 800% in 5 years. Biotricity (BTCY) is the most recent entrant into the remote monitoring space with their first FDA clearance in December. The launch of Bioflux, an advanced remote ECG monitoring device, is underway and first sales should emerge in the coming months after having signed some respected anchor clients.

  • ACCESSWIRElast month

    Free Pre-Market Technical Recap on TherapeuticsMD and Three Additional Healthcare Stocks

    LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).

  • Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher
    Zackslast month

    Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher

    Zogenix (ZGNX) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Zogenix and Momenta Pharmaceuticals

    While the Dow reclaimed its above 25,000 levels after almost a month Nasdaq is at a record high. The Dow Jones Industrial Average gained 0.38 percent to close at 25,019.41, while the S&P 500 Index increased 0.11 percent to close at 2,801.31. The Nasdaq Composite Index climbed 0.03 percent to close at 7,825.98.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks get even hotter?

  • Why Zogenix Inc. Shares Jumped 10% on Friday
    Motley Foollast month

    Why Zogenix Inc. Shares Jumped 10% on Friday

    Wall Street is cheering the latest data for the company's epilepsy drug.

  • Zogenix's Epilepsy Candidate Successful in Phase III Study
    Zackslast month

    Zogenix's Epilepsy Candidate Successful in Phase III Study

    Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...

  • Why Twitter, Papa John's International, and Zogenix Jumped Today
    Motley Foollast month

    Why Twitter, Papa John's International, and Zogenix Jumped Today

    The market cheered after one of these companies distanced itself from its founder.

  • Zogenix Stock Soars on Positive Clinical Trial Results
    Market Realistlast month

    Zogenix Stock Soars on Positive Clinical Trial Results

    Today, Zogenix stock is trading at $55.72, which represents a ~20.35% rise from yesterday’s close of $46.30. Zogenix also hit a 52-week high of $58.30 today, and yesterday’s closing price was ~361% higher than its 52-week low of $10.05 on August 11, 2017.